
|Videos|August 3, 2015
Will Biosimilars Impact the Cost of Specialty Drugs?
Author(s)Davy James, Managing Editor
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Advertisement
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























